Company news
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) news
Neonc Technologies Holdings, Inc. news releases on 6ix. Latest, Sep 29, 2026: NeOnc’s Powerful Brain Cancer Pipeline Advances
Press releases & updates
NeOnc’s Powerful Brain Cancer Pipeline Advances
September 28, 2026
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
September 28, 2026
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
September 17, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
September 16, 2026
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
September 9, 2026
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
August 13, 2026
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
August 12, 2026
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
August 11, 2026
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
August 10, 2026
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
August 10, 2026
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
July 27, 2026
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
July 15, 2026
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
June 23, 2026
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
June 23, 2026
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
June 22, 2026
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
June 15, 2026
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
May 18, 2026
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
May 5, 2026
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
April 14, 2026
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
March 31, 2026
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
March 12, 2026
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
March 12, 2026
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
March 3, 2026
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
February 26, 2026
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
January 30, 2026
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
January 8, 2026
NeOnc Technologies Reports Updated Clinical Results
December 15, 2025
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
December 1, 2025
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
November 14, 2025
NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
November 13, 2025
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
November 7, 2025
NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
November 4, 2025
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
October 28, 2025
Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC
October 10, 2025
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
October 9, 2025
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
October 6, 2025
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
October 2, 2025
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
October 1, 2025
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
September 29, 2025
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
September 22, 2025
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
September 10, 2025
TexPower Appoints Bader Almonawer as President to Lead U.S. Lithium-Ion Battery Manufacturing Into the Future
September 4, 2025
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
August 25, 2025
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
August 19, 2025
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
August 11, 2025
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
August 11, 2025
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
August 7, 2025
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
August 4, 2025
New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards
July 30, 2025
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
July 30, 2025